Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 2003 Apr;49:449–457.

What to do if an initial antidepressant fails?

Roger S McIntyre 1, Aleksandra Müller 1, Deborah A Mancini 1, Eric S Silver 1
PMCID: PMC2214210  PMID: 12729241

Abstract

OBJECTIVE: To provide family physicians with practical ways of managing depressed patients responding insufficiently to initial antidepressant treatment. QUALITY OF EVIDENCE: A search of MEDLINE and relevant bibliographies showed most studies could be categorized as level III evidence. Few well controlled studies (eg, level I evidence) specify treatment of next choice in rigorously defined treatment-refractory depression (TRD). MAIN MESSAGE: Failure to achieve and sustain full symptom remission affects relatively few treated depressed patients. Most chronically depressed people are not absolutely resistant but are relatively resistant to treatment; they fail to achieve the goals of treatment because of improper diagnosis or insufficient treatment application. The literature on TRD has largely focused on medication strategies; fewer studies investigated psychosocial approaches. The best established augmentation strategies are lithium salts and triidothyronine (T3). Combination antidepressants have become clinical psychiatrists' preferred treatment, despite limited evidence. Electroconvulsive therapy (ECT) remains a feasible option for TRD, but response rates are poor among people with TRD. High relapse rates after ECT remain a serious and common clinical dilemma. CONCLUSION: Family physicians should familiarize themselves with some new strategies to modify inadequate response to initial antidepressant treatment.

Full Text

The Full Text of this article is available as a PDF (270.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altshuler L. L., Bauer M., Frye M. A., Gitlin M. J., Mintz J., Szuba M. P., Leight K. L., Whybrow P. C. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001 Oct;158(10):1617–1622. doi: 10.1176/appi.ajp.158.10.1617. [DOI] [PubMed] [Google Scholar]
  2. Appelberg B. G., Syvälahti E. K., Koskinen T. E., Mehtonen O. P., Muhonen T. T., Naukkarinen H. H. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001 Jun;62(6):448–452. doi: 10.4088/jcp.v62n0608. [DOI] [PubMed] [Google Scholar]
  3. Aronson R., Offman H. J., Joffe R. T., Naylor C. D. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996 Sep;53(9):842–848. doi: 10.1001/archpsyc.1996.01830090090013. [DOI] [PubMed] [Google Scholar]
  4. Bauer M., Bschor T., Kunz D., Berghöfer A., Ströhle A., Müller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry. 2000 Sep;157(9):1429–1435. doi: 10.1176/appi.ajp.157.9.1429. [DOI] [PubMed] [Google Scholar]
  5. Carpenter L. L., Jocic Z., Hall J. M., Rasmussen S. A., Price L. H. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry. 1999 Jan;60(1):45–49. doi: 10.4088/jcp.v60n0110. [DOI] [PubMed] [Google Scholar]
  6. Claxton A. J., Li Z., McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry. 2000 Aug;177:163–168. doi: 10.1192/bjp.177.2.163. [DOI] [PubMed] [Google Scholar]
  7. Druss B. G., Hoff R. A., Rosenheck R. A. Underuse of antidepressants in major depression: prevalence and correlates in a national sample of young adults. J Clin Psychiatry. 2000 Mar;61(3):234–239. [PubMed] [Google Scholar]
  8. Fava G. A., Savron G., Grandi S., Rafanelli C. Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry. 1997 Jun;58(6):278–284. doi: 10.4088/jcp.v58n0608b. [DOI] [PubMed] [Google Scholar]
  9. FitzSimmons C. R., Metha S. Serotonin syndrome caused by overdose with paroxetine and moclobemide. J Accid Emerg Med. 1999 Jul;16(4):293–295. doi: 10.1136/emj.16.4.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Frank E., Grochocinski V. J., Spanier C. A., Buysse D. J., Cherry C. R., Houck P. R., Stapf D. M., Kupfer D. J. Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. J Clin Psychiatry. 2000 Jan;61(1):51–57. [PubMed] [Google Scholar]
  11. Fredman S. J., Fava M., Kienke A. S., White C. N., Nierenberg A. A., Rosenbaum J. F. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000 Jun;61(6):403–408. doi: 10.4088/jcp.v61n0602. [DOI] [PubMed] [Google Scholar]
  12. Frye M. A., Ketter T. A., Leverich G. S., Huggins T., Lantz C., Denicoff K. D., Post R. M. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000 Jan;61(1):9–15. doi: 10.4088/jcp.v61n0104. [DOI] [PubMed] [Google Scholar]
  13. Furukawa T. A., Kitamura T., Takahashi K. Time to recovery of an inception cohort with hitherto untreated unipolar major depressive episodes. Br J Psychiatry. 2000 Oct;177:331–335. doi: 10.1192/bjp.177.4.331. [DOI] [PubMed] [Google Scholar]
  14. Gyulai L., Bauer M., Garcia-Espana F., Hierholzer J., Baumgartner A., Berghöfer A., Whybrow P. C. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord. 2001 Oct;66(2-3):185–191. doi: 10.1016/s0165-0327(00)00306-2. [DOI] [PubMed] [Google Scholar]
  15. Gyulai L., Jaggi J., Bauer M. S., Younkin S., Rubin L., Attie M., Whybrow P. C. Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder. Biol Psychiatry. 1997 Feb 15;41(4):503–506. doi: 10.1016/S0006-3223(96)00472-6. [DOI] [PubMed] [Google Scholar]
  16. Hirschfeld R. M., Williams J. B., Spitzer R. L., Calabrese J. R., Flynn L., Keck P. E., Jr, Lewis L., McElroy S. L., Post R. M., Rapport D. J. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000 Nov;157(11):1873–1875. doi: 10.1176/appi.ajp.157.11.1873. [DOI] [PubMed] [Google Scholar]
  17. Joffe R. T., Levitt A. J., Bagby R. M., MacDonald C., Singer W. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry. 1993 Nov;163:574–578. doi: 10.1192/bjp.163.5.574. [DOI] [PubMed] [Google Scholar]
  18. Judd L. L., Paulus M. J., Schettler P. J., Akiskal H. S., Endicott J., Leon A. C., Maser J. D., Mueller T., Solomon D. A., Keller M. B. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000 Sep;157(9):1501–1504. doi: 10.1176/appi.ajp.157.9.1501. [DOI] [PubMed] [Google Scholar]
  19. Katon W., Von Korff M., Lin E., Lipscomb P., Russo J., Wagner E., Polk E. Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry. 1990 Nov;12(6):355–362. doi: 10.1016/0163-8343(90)90002-t. [DOI] [PubMed] [Google Scholar]
  20. Keller M. B., McCullough J. P., Klein D. N., Arnow B., Dunner D. L., Gelenberg A. J., Markowitz J. C., Nemeroff C. B., Russell J. M., Thase M. E. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18;342(20):1462–1470. doi: 10.1056/NEJM200005183422001. [DOI] [PubMed] [Google Scholar]
  21. Kennedy S. H., Lam R. W., Cohen N. L., Ravindran A. V., CANMAT Depression Work Group Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry. 2001 Jun;46 (Suppl 1):38S–58S. [PubMed] [Google Scholar]
  22. Kennedy Sidney H., McCann Sonia M., Masellis Mario, McIntyre Roger S., Raskin Joel, McKay Gordon, Baker Glen B. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002 Mar;63(3):181–186. doi: 10.4088/jcp.v63n0302. [DOI] [PubMed] [Google Scholar]
  23. Kessler R. C., Soukup J., Davis R. B., Foster D. F., Wilkey S. A., Van Rompay M. I., Eisenberg D. M. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry. 2001 Feb;158(2):289–294. doi: 10.1176/appi.ajp.158.2.289. [DOI] [PubMed] [Google Scholar]
  24. Landén M., Björling G., Agren H., Fahlén T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998 Dec;59(12):664–668. [PubMed] [Google Scholar]
  25. Landén M., Eriksson E., Agren H., Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999 Jun;19(3):268–271. doi: 10.1097/00004714-199906000-00012. [DOI] [PubMed] [Google Scholar]
  26. Laukkala T., Isometsä E., Hämäläinen J., Heikkinen M., Lindeman S., Aro H. Antidepressant treatment of depression in the Finnish general population. Am J Psychiatry. 2001 Dec;158(12):2077–2079. doi: 10.1176/appi.ajp.158.12.2077. [DOI] [PubMed] [Google Scholar]
  27. Lecrubier Y. The burden of depression and anxiety in general medicine. J Clin Psychiatry. 2001;62 (Suppl 8):4–11. [PubMed] [Google Scholar]
  28. Levitan R. D., Shen J. H., Jindal R., Driver H. S., Kennedy S. H., Shapiro C. M. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. J Psychiatry Neurosci. 2000 Sep;25(4):337–346. [PMC free article] [PubMed] [Google Scholar]
  29. Lin E. H., Von Korff M., Katon W., Bush T., Simon G. E., Walker E., Robinson P. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995 Jan;33(1):67–74. doi: 10.1097/00005650-199501000-00006. [DOI] [PubMed] [Google Scholar]
  30. Lish J. D., Dime-Meenan S., Whybrow P. C., Price R. A., Hirschfeld R. M. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994 Aug;31(4):281–294. doi: 10.1016/0165-0327(94)90104-x. [DOI] [PubMed] [Google Scholar]
  31. Londborg P. D., Smith W. T., Glaudin V., Painter J. R. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. J Affect Disord. 2000 Dec;61(1-2):73–79. doi: 10.1016/s0165-0327(99)00195-0. [DOI] [PubMed] [Google Scholar]
  32. Lépine J. P. Epidemiology, burden, and disability in depression and anxiety. J Clin Psychiatry. 2001;62 (Suppl 13):4–12. [PubMed] [Google Scholar]
  33. Lépine J. P., Gastpar M., Mendlewicz J., Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol. 1997 Jan;12(1):19–29. [PubMed] [Google Scholar]
  34. Murray C. J., Lopez A. D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997 May 24;349(9064):1498–1504. doi: 10.1016/S0140-6736(96)07492-2. [DOI] [PubMed] [Google Scholar]
  35. Nelson J. C. Augmentation strategies in depression 2000. J Clin Psychiatry. 2000;61 (Suppl 2):13–19. [PubMed] [Google Scholar]
  36. Nelson J. C. Augmentation strategies with serotonergic-noradrenergic combinations. J Clin Psychiatry. 1998;59 (Suppl 5):65–69. [PubMed] [Google Scholar]
  37. Nelson J. C., Mazure C. M., Jatlow P. I. Characteristics of desipramine-refractory depression. J Clin Psychiatry. 1994 Jan;55(1):12–19. [PubMed] [Google Scholar]
  38. Nemeroff C. B. Augmentation strategies in patients with refractory depression. Depress Anxiety. 1996;4(4):169–181. doi: 10.1002/(SICI)1520-6394(1996)4:4<169::AID-DA3>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  39. Nierenberg A. A., Farabaugh A. H., Alpert J. E., Gordon J., Worthington J. J., Rosenbaum J. F., Fava M. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000 Sep;157(9):1423–1428. doi: 10.1176/appi.ajp.157.9.1423. [DOI] [PubMed] [Google Scholar]
  40. O'Leary D., Costello F., Gormley N., Webb M. Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients. J Affect Disord. 2000 Jan-Mar;57(1-3):159–171. doi: 10.1016/s0165-0327(99)00086-5. [DOI] [PubMed] [Google Scholar]
  41. Orrell M., Collins E., Shergill S., Katona C. Management of depression in the elderly by general practitioners: I. Use of antidepressants. Fam Pract. 1995 Mar;12(1):5–11. doi: 10.1093/fampra/12.1.5. [DOI] [PubMed] [Google Scholar]
  42. Ostroff R. B., Nelson J. C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999 Apr;60(4):256–259. doi: 10.4088/jcp.v60n0410. [DOI] [PubMed] [Google Scholar]
  43. Parikh S. V., Lesage A. D., Kennedy S. H., Goering P. N. Depression in Ontario: under-treatment and factors related to antidepressant use. J Affect Disord. 1999 Jan-Mar;52(1-3):67–76. doi: 10.1016/s0165-0327(98)00063-9. [DOI] [PubMed] [Google Scholar]
  44. Parikh S. V., Lin E., Lesage A. D. Mental health treatment in Ontario: selected comparisons between the primary care and specialty sectors. Can J Psychiatry. 1997 Nov;42(9):929–934. doi: 10.1177/070674379704200903. [DOI] [PubMed] [Google Scholar]
  45. Penninx B. W., Beekman A. T., Honig A., Deeg D. J., Schoevers R. A., van Eijk J. T., van Tilburg W. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. 2001 Mar;58(3):221–227. doi: 10.1001/archpsyc.58.3.221. [DOI] [PubMed] [Google Scholar]
  46. Rudolph R. L. Goal of antidepressant therapy: response or remission and recovery? J Clin Psychiatry. 1999;60 (Suppl 6):3–4. [PubMed] [Google Scholar]
  47. Sackeim H. A., Haskett R. F., Mulsant B. H., Thase M. E., Mann J. J., Pettinati H. M., Greenberg R. M., Crowe R. R., Cooper T. B., Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001 Mar 14;285(10):1299–1307. doi: 10.1001/jama.285.10.1299. [DOI] [PubMed] [Google Scholar]
  48. Sartorius N., Ustün T. B., Costa e Silva J. A., Goldberg D., Lecrubier Y., Ormel J., Von Korff M., Wittchen H. U. An international study of psychological problems in primary care. Preliminary report from the World Health Organization Collaborative Project on 'Psychological Problems in General Health Care'. Arch Gen Psychiatry. 1993 Oct;50(10):819–824. doi: 10.1001/archpsyc.1993.01820220075008. [DOI] [PubMed] [Google Scholar]
  49. Shad M. U., Preskorn S. H. A possible bupropion and imipramine interaction. J Clin Psychopharmacol. 1997 Apr;17(2):118–119. doi: 10.1097/00004714-199704000-00011. [DOI] [PubMed] [Google Scholar]
  50. Shaw K., Turner J., Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2001;(3):CD003198–CD003198. doi: 10.1002/14651858.CD003198. [DOI] [PubMed] [Google Scholar]
  51. Shelton R. C., Tollefson G. D., Tohen M., Stahl S., Gannon K. S., Jacobs T. G., Buras W. R., Bymaster F. P., Zhang W., Spencer K. A. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001 Jan;158(1):131–134. doi: 10.1176/appi.ajp.158.1.131. [DOI] [PubMed] [Google Scholar]
  52. Sheps D. S., Sheffield D. Depression, anxiety, and the cardiovascular system: the cardiologist's perspective. J Clin Psychiatry. 2001;62 (Suppl 8):12–18. [PubMed] [Google Scholar]
  53. Steiner M., Bell B., Browne G., Roberts J., Gafni A., Byrne C., Dunn E., Chalkin L., Kraemer J., Mills M. Prevalence of dysthymic disorder in primary care. J Affect Disord. 1999 Aug;54(3):303–308. doi: 10.1016/s0165-0327(98)00189-x. [DOI] [PubMed] [Google Scholar]
  54. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991 Jun;148(6):705–713. doi: 10.1176/ajp.148.6.705. [DOI] [PubMed] [Google Scholar]
  55. Thase M. E., Howland R. H., Friedman E. S. Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry. 1998;59 (Suppl 5):5–15. [PubMed] [Google Scholar]
  56. Thase M. E. Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry. 1999;60 (Suppl 6):15–19. [PubMed] [Google Scholar]
  57. Thase M. E. Relapse and recurrence in unipolar major depression: short-term and long-term approaches. J Clin Psychiatry. 1990 Jun;51 (Suppl):51–59. [PubMed] [Google Scholar]
  58. Thase M. E., Rush A. J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 (Suppl 13):23–29. [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES